THERAPY DOSSIER · th-6b82941007d0

Nimodipine with dextran 40

Drug · Voltage-gated L-type calcium channel blocker (BLOCKER); mineralocorticoid receptor antagonist (ANTAGONIST). Approved 1988, black box warning, ATC C08CA06. Co-agent dextran 40 matches ChEMBL2109168 (DEXTRAN 40, max_phase 2) and CHEMBL1697742 (DEXTRAN, max_phase 3), a low-molecular-weight plasma volume expander with no ChEMBL MoA record.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Voltage-gated L-type calcium channel blocker (BLOCKER); mineralocorticoid receptor antagonist (ANTAGONIST). Approved 1988, black box warning, ATC C08CA06. Co-agent dextran 40 matches ChEMBL2109168 (DEXTRAN 40, max_phase 2) and CHEMBL1697742 (DEXTRAN, max_phase 3), a low-molecular-weight plasma volume expander with no ChEMBL MoA record.
Target: CHEMBL2095229 (voltage-gated L-type calcium channel); CHEMBL1994 (mineralocorticoid receptor)
Injury models: Spinal cord injury
Reported indication: Improvement of neurological outcome after aneurysmal subarachnoid haemorrhage by reducing incidence/severity of ischaemic deficits (FDA-approved 1988, Nimotop; ATC C08CA06)
First approval: 1988
Development stage: Approved for aneurysmal SAH; black-box on parenteral route
ChEMBL record: CHEMBL1428 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Nimotop; Nymalize; BAY E 9736; Nimodipino; Periplum; Admon; Nemotan; NSC-758476
Note: Not recorded

Clinical trials 7

3 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT07144956 ↗Injury indicationPHASE3not yet recruiting

Trial title not recorded

Aneurysmal Subarachnoid Hemorrhage

Enrolment: 630 · Results not recorded

NCT05131867 ↗Injury indicationPHASE2completed

Trial title not recorded

Vascular Spasm After Traumatic Subarachnoid Haemorrhage

Enrolment: 30 · Results not recorded

NCT04311840 ↗Injury indicationNAunknown

Trial title not recorded

Subarachnoid Hemorrhage

Enrolment: 30 · Results not recorded

NCT03925025 ↗PHASE3completed

Trial title not recorded

Anticholinesterase Insecticide Poisoning · Pesticide Poisoning

Enrolment: 1728 · Results not recorded

NCT02767154 ↗PHASE2completed

Trial title not recorded

Heart Disease

Enrolment: 84 · Results not recorded

NCT01672801 ↗NAcompleted

Trial title not recorded

Unexplained Infertility · Polycystic Ovarian Syndrome · Anovulatory

Enrolment: 18 · Results posted

NCT06835023 ↗NArecruiting

Trial title not recorded

Acute Pancreatitis

Enrolment: 100 · Results not recorded

Preclinical evidence 2

2 studies reported at therapy level; 2 evidence entries itemised.

PMID 2475595 ↗1989Mixed findings

The effect of nimodipine and dextran on axonal function and blood flow following experimental spinal cord injury.

RatSpinal cord injuryCompressionn = 30 rats, six treatment groups of fiveIntravenous infusionNimodipine 0.02 mg/kg or 0.05 mg/kg, with or without dextra…Infusion commenced 1 h after injury

Model: 53 g clip compression injury of the spinal cord at T-1

Injury reduced spinal cord blood flow from 56.84 to 24.55 ml/100 g/min with significant evoked potential changes. Only nimodipine 0.02 mg/kg combined with dextran 40 raised blood flow to 43.69 ml/100 g/min and improved cord and nerve motor evoked potentials and somatosensory evoked potentials; othe…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

PMID 32295897 ↗2020Reported benefit

Early delivery and prolonged treatment with nimodipine prevents the development of spasticity after spinal cord injury in mice.

MouseSpinal cord injuryUnspecifiedStarted in the acute phase after spinal cord injury

Model: Chronic spinal cord injury model in mice

Nimodipine started in the acute phase completely prevented development of spasticity, measured as increased muscle tone and spontaneous spasms. The inhibition of aberrant muscle activity persisted after treatment ended, and Cav1.3 was shown to mediate the effect.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Record at a glance

Study window: 1989–2020
Corpus tranches: 1980-1989 · 2011-2020
Species: Mouse · Rat
Physical-trauma evidence: Present
Repurposed: Approval pre-dates corpus studies
Combination: Not flagged
Withdrawal flag: Not flagged
Dataset: 2026-08-25

Safety narrative

Reported finding

Boxed warning: death and serious life-threatening events after inadvertent IV administration of capsule contents; IV solution not FDA-approved in US

The supplied narrative describes a warning, adverse event, restriction or clinical finding. Context and indication must be checked in the original sources; this is not an independent safety assessment.

Sources & provenance

ChEMBL (EMBL-EBI) CHEMBL1428 max_phase 4, black_box true
FDA Nimotop label accessdata.fda.gov/drugsatfda_docs/label/2006/018869s014lbl.pdf
StatPearls Nimodipine (NCBI NBK534870)
ClinicalTrials.gov (NIH/NLM) NCT05131867

How records are classified

Loading the evidence…

Nimodipine with dextran 40